Firms on GLP-1 import records
Which firms and countries appear in FDA import records for GLP-1 drugs?
FDA’s Import Alert 66-80, published Oct 9, 2026, says FDA divisions “may detain without physical examination (DWPE) shipments of GLP-1 APIs offered for entry, except for the products and firms identified on the Green List.” The Green List has 21 entries: China (12), India (3), Belgium (1), Canada (1), Denmark (1), Ireland (1), Italy (1) and Portugal (1). FDA redacts every Green List firm name, so the list shows countries and drugs, not companies. FDA’s import refusal records list 717 refused shipment lines whose product code names semaglutide, tirzepatide, liraglutide, retatrutide or GLP-1, dated Jun 16, 2023 to Oct 30, 2026; 32 of them carry an API or powder product code listed on the alert, most often from China (27), Hong Kong (2) and Canada (1).
Records read Nov 15, 2026. Import refusal files searched cover Jan 1, 2002 to Oct 30, 2026. A refusal line is one product line on an import entry that FDA refused; the declared manufacturer is the firm the importer named, not necessarily the firm that made the product.
Answer pages: Where does compounded semaglutide API come from? FDA import records by country, What is FDA’s GLP-1 API Green List (Import Alert 66-80)?, How many GLP-1 import shipments has FDA refused, and from which countries?.
Import Alert 66-80 Green List
Import Alert 66-80, “Detention Without Physical Examination of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Bulk Drug Substances” (DWPE, published Oct 9, 2026). FDA’s heading for the list: “List of firms and their drugs that have met the criteria for exclusion from recommendation for Detention Without Physical Examination (DWPE) under this Import Alert (a.k.a. Green List)” The entries below are in FDA’s order; FDA prints a redaction in place of each firm name.
| Product codes and drugs listed | |||
|---|---|---|---|
| 1 | Redacted by FDA | BELGIUM | 61P[][]72 Semaglutide (Anti-Diabetic) 61P[][]75 Exenatide (Anti-Diabetic) |
| 2 | Redacted by FDA | CANADA | 61P[][]74 Tirzepatide (Anti-Diabetic) |
| 3 | Redacted by FDA | CHINA | 56F[][]99 Peptide N.E.C. (Antibiotics), and the importer description contains the word, [redacted] 61P[][]77 Orforglipron (Anti-Diabetic) 61P[][]99 Anti-Diabetic N.E.C. (Anti-Diabetic) and the importer description contains the word, [redacted] 61P[][]99 Anti-Diabetic N.E.C. (Anti-Diabetic) [redacted] |
| 4 | Redacted by FDA | CHINA | 56F[][]99 Peptide N.E.C. (Antibiotics) 61P[][]72 Semaglutide (Anti-Diabetic) 61P[][]99 Anti-Diabetic N.E.C. (Anti-Diabetic) |
| 5 | Redacted by FDA | CHINA | 61P[][]76 Liraglutide (Anti-Diabetic) 61P[][]72 Semaglutide (Anti-Diabetic) 61P[][]74 Tirzepatide (Anti-Diabetic) |
| 6 | Redacted by FDA | CHINA | 61P[][]74 Tirzepatide (Anti-Diabetic) |
| 7 | Redacted by FDA | CHINA | 61P[][]76 Liraglutide (Anti-Diabetic) 61P[][]72 Semaglutide (Anti-Diabetic) 61P[][]74 Tirzepatide (Anti-Diabetic) |
| 8 | Redacted by FDA | CHINA | 61P[][]76 Liraglutide (Anti-Diabetic) 61P[][]72 Semaglutide (Anti-Diabetic) 61P[][]74 Tirzepatide (Anti-Diabetic) |
| 9 | Redacted by FDA | CHINA | 61P[][]76 Liraglutide (Anti-Diabetic) |
| 10 | Redacted by FDA | CHINA | 61P[][]76 Liraglutide (Anti-Diabetic) 61P[][]72 Semaglutide (Anti-Diabetic) 61P[][]74 Tirzepatide (Anti-Diabetic) |
| 11 | Redacted by FDA | CHINA | 61P[][]74 Tirzepatide (Anti-Diabetic) 61P[][]77 Orforglipron (Anti-Diabetic) |
| 12 | Redacted by FDA | CHINA | 61P[][]72 Semaglutide (Anti-Diabetic) 61P[][]74 Tirzepatide (Anti-Diabetic) |
| 13 | Redacted by FDA | CHINA | 61P[][]76 Liraglutide (Anti-Diabetic) 61P[][]72 Semaglutide (Anti-Diabetic) 61P[][]74 Tirzepatide (Anti-Diabetic) |
| 14 | Redacted by FDA | CHINA | 56F[][]99 Peptide N.E.C. (Antibiotics) [redacted] 61P[][]99 Anti-Diabetic N.E.C. (Anti-Diabetic) [redacted] 64R[][]99 Hormone N.E.C. (Hormone) [redacted] |
| 15 | Redacted by FDA | DENMARK | 61P[][]76 Liraglutide (Anti-Diabetic) 61P[][]72 Semaglutide (Anti-Diabetic) |
| 16 | Redacted by FDA | INDIA | 61P[][]76 Liraglutide (Anti-Diabetic) |
| 17 | Redacted by FDA | INDIA | 61P[][]75 Exenatide (Anti-Diabetic) |
| 18 | Redacted by FDA | INDIA | 61P[][]76 Liraglutide (Anti-Diabetic) |
| 19 | Redacted by FDA | IRELAND | 58H[][]06 Dulaglutide (Endocrine-Metabolic Agent) 61P[][]77 Orforglipron (Anti-Diabetic) |
| 20 | Redacted by FDA | PORTUGAL | 61P[][]72 Semaglutide (Anti-Diabetic) 61P[][]77 Orforglipron SDD (Anti-Diabetic) |
| 21 | Redacted by FDA | ITALY | 61P[][]76 Liraglutide (Anti-Diabetic) |
More on what the list is and the alert’s full reason text: What is FDA’s GLP-1 API Green List?
Refused GLP-1 shipment lines by country
All 717 lines, and the 32 whose product code Import Alert 66-80 lists as an API or powder form.
| Country | All lines | API or powder code lines |
|---|---|---|
| Canada | 251 | 1 |
| Denmark | 149 | 0 |
| United States | 59 | 0 |
| China | 42 | 27 |
| United Kingdom | 42 | 0 |
| India | 32 | 0 |
| Colombia | 19 | 0 |
| Italy | 13 | 0 |
| Mexico | 13 | 0 |
| Japan | 11 | 0 |
| Bangladesh | 10 | 0 |
| Brazil | 9 | 0 |
| France | 9 | 0 |
| Netherlands | 7 | 0 |
| Turkey | 7 | 0 |
| Germany | 6 | 1 |
| Vietnam | 6 | 0 |
| Hong Kong | 5 | 2 |
| Singapore | 4 | 0 |
| Lithuania | 3 | 0 |
| Switzerland | 3 | 1 |
| Israel | 2 | 0 |
| Nigeria | 2 | 0 |
| Philippines | 2 | 0 |
| Albania | 1 | 0 |
| Australia | 1 | 0 |
| Bulgaria | 1 | 0 |
| Egypt | 1 | 0 |
| Greece | 1 | 0 |
| Honduras | 1 | 0 |
| Indonesia | 1 | 0 |
| Paraguay | 1 | 0 |
| Poland | 1 | 0 |
| Portugal | 1 | 0 |
| United States Outlying Islands | 1 | 0 |
By drug named in the product code
| Semaglutide | 501 |
| Tirzepatide | 201 |
| Retatrutide | 11 |
| Liraglutide | 4 |
Firms named as manufacturer on refused GLP-1 lines
67 firms have a page, one per spelling and country as FDA wrote it. The declared manufacturer is the name the importer entered on the line.
| Fujian Genohope Biotech Ltd | China | 9 | 7 | Tirzepatide, Semaglutide | May 28, 2025 |
| Zhejiang Peptites Biotech Co.,Ltd. | China | 6 | 4 | Tirzepatide, Semaglutide | Mar 15, 2024 |
| ELIE PHARMACY | Canada | 5 | 0 | Semaglutide | May 13, 2024 |
| Incepta Pharmaceuticals Ltd | Bangladesh | 5 | 0 | Semaglutide | Feb 7, 2026 |
| Pharmazon | United Kingdom | 5 | 0 | Semaglutide, Tirzepatide | Oct 24, 2025 |
| Qingdao Biopeptek Co., Ltd. | China | 4 | 3 | Semaglutide, Tirzepatide | Jan 25, 2024 |
| SHREE PHARMA | India | 4 | 0 | Tirzepatide | Jan 9, 2026 |
| COMEM NATURAL JSC | Vietnam | 3 | 0 | Retatrutide | Sep 24, 2026 |
| N EDGE GROUP INC | Canada | 3 | 0 | Retatrutide | Aug 25, 2026 |
| XU LIHUA JINGFANG Trading Co. LTD | China | 3 | 2 | Retatrutide, Tirzepatide, Semaglutide | Oct 7, 2026 |
| Ziska Pharmaceuticals Ltd. | India | 3 | 0 | Tirzepatide, Semaglutide | May 4, 2026 |
| BRITANNICA REMEDY'S RX PHARMACY | Canada | 2 | 0 | Semaglutide | Dec 18, 2025 |
| CMB MEDICINA UAB | Lithuania | 2 | 0 | Tirzepatide | Jun 20, 2025 |
| DAY PHARMA EIRELI | Brazil | 2 | 0 | Semaglutide | May 22, 2024 |
| Hangzhou ThinHeal Pharma-Tech Co., Ltd. | China | 2 | 2 | Semaglutide, Tirzepatide | May 1, 2025 |
| Harbin Jixianglong Biotech Co., Ltd. | China | 2 | 1 | Semaglutide, Tirzepatide | Aug 6, 2025 |
| Hybio Pharmaceutical Co., Ltd. | China | 2 | 1 | Semaglutide, Tirzepatide | Jun 30, 2026 |
| PARKWAY PHARMACY | Canada | 2 | 0 | Tirzepatide, Semaglutide | Jan 3, 2025 |
| ROYALDAY COMPANY LIMITED | Hong Kong | 2 | 0 | Semaglutide | Jan 28, 2026 |
| SHANGHAI SHUNYI TRADE CO LTD | China | 2 | 1 | Tirzepatide, Retatrutide | Oct 7, 2026 |
| ZISKA PHARMA | Bangladesh | 2 | 0 | Tirzepatide | May 5, 2026 |
| ACI PHARMACEUTICALS LTD | Bangladesh | 1 | 0 | Tirzepatide | Aug 15, 2024 |
| AndersonBrecon Inc. | United States | 1 | 0 | Tirzepatide | Jun 18, 2026 |
| AP CARGO INTERNATIONAL FREIGHT INC. | Philippines | 1 | 0 | Semaglutide | Sep 23, 2024 |
| APSIN PHARMACEUTICAL LTD | India | 1 | 0 | Tirzepatide | Jun 18, 2025 |
| ASIAN SUITS ONLINE LIMITED | United Kingdom | 1 | 0 | Semaglutide | Jul 13, 2026 |
| BELJING YIYUAN TECHNOLOGY GROUP | China | 1 | 0 | Tirzepatide | Dec 10, 2025 |
| BIOAMINO LABS | Germany | 1 | 1 | Tirzepatide | Sep 14, 2026 |
| Cayman Chemical Company, Inc. | United States | 1 | 0 | Semaglutide | Nov 1, 2024 |
| CELEB CLINIC | Nigeria | 1 | 0 | Semaglutide | May 31, 2024 |
| CHONGUHAN MEDICAL TECHNOLOGIES | China | 1 | 0 | Tirzepatide | Jul 24, 2026 |
| DALIAN HANDOM CHEM | China | 1 | 0 | Semaglutide | Feb 13, 2024 |
| DROGUERIA LA REBAJA PLUS | Colombia | 1 | 0 | Semaglutide | Nov 12, 2024 |
| DYNAMIC GROUP | Canada | 1 | 1 | Tirzepatide | May 19, 2025 |
| ELIE WELLNESS | Canada | 1 | 0 | Semaglutide | Sep 26, 2024 |
| FELIX HEALTH | Canada | 1 | 0 | Semaglutide | Aug 8, 2025 |
| Gene Proteins | Switzerland | 1 | 1 | Tirzepatide | Feb 25, 2026 |
| HONG KONG KAIYS TRADING LIMITED | Hong Kong | 1 | 1 | Tirzepatide | Feb 3, 2026 |
| Hubei JXBio Pharmaceutical Co., Ltd. | China | 1 | 1 | Tirzepatide | Aug 5, 2024 |
| Hybio Pharmaceutical (Wuhan) Co., Ltd. | China | 1 | 1 | Semaglutide | May 14, 2026 |
| JASONS CANDA DRUGSTORE | Canada | 1 | 0 | Semaglutide | May 13, 2024 |
| JB PHARMA | India | 1 | 0 | Tirzepatide | Dec 5, 2025 |
| JBL INTERNATIONAL HK LIMITED | Hong Kong | 1 | 1 | Tirzepatide | Apr 30, 2024 |
| Lifecar Neuro Products Ltd | India | 1 | 0 | Tirzepatide | May 28, 2025 |
| Marks Marine Pharmacy | Canada | 1 | 0 | Semaglutide | Feb 20, 2026 |
| MetaTide Healthcare | Switzerland | 1 | 0 | Retatrutide | Oct 2, 2026 |
| NANJING HANXIN INTERNATIONAL | China | 1 | 1 | Semaglutide | May 19, 2026 |
| NOVO PHARMA | Canada | 1 | 0 | Semaglutide | Dec 12, 2025 |
| PASTURE PHARMA PTE LTD | Singapore | 1 | 0 | Semaglutide | Aug 26, 2025 |
| PB PHARMA GMBH | Germany | 1 | 0 | Semaglutide | Apr 12, 2024 |
| PEPTIDE SCIENCES | India | 1 | 0 | Tirzepatide | Dec 18, 2025 |
| Pharmhub Pharmacy | United Kingdom | 1 | 0 | Semaglutide | Jun 12, 2026 |
| SENOVA BIOPHARM CO LTD | Hong Kong | 1 | 0 | Tirzepatide | Nov 10, 2025 |
| SHARMA BROTHER'S INTERNATIONAL | India | 1 | 0 | Tirzepatide | Jun 21, 2024 |
| SHENZHEN JYMED TECHNOLOGY CO., LTD. | China | 1 | 1 | Tirzepatide | Nov 27, 2023 |
| SIMPLIPHARM PHARMACY | Canada | 1 | 0 | Semaglutide | Aug 8, 2025 |
| SLG DELIVERY SERVICES | Canada | 1 | 0 | Semaglutide | Feb 18, 2025 |
| SUNGLOW LIFESCIENCE PRIVATE LTD | India | 1 | 0 | Semaglutide | Mar 3, 2025 |
| Suzhou Tianma Pharma Group Tianji Bio-Pharmaceutical Co., Ltd. | China | 1 | 0 | Semaglutide | Jul 26, 2023 |
| Synokem Pharmaceuticals Ltd | India | 1 | 0 | Tirzepatide | May 29, 2026 |
| VS HEALTHCARE | India | 1 | 0 | Semaglutide | Aug 23, 2023 |
| Westin Resort & Spa | Canada | 1 | 0 | Semaglutide | May 27, 2026 |
| XIAMEN YUANJINCHEN TRADING CO,.LTD | China | 1 | 1 | Tirzepatide | May 14, 2025 |
| Yangzhou Aurisco Pharmaceutical Co., Ltd. | China | 1 | 0 | Semaglutide | Jun 20, 2025 |
| YOU DRUG MART | Canada | 1 | 0 | Semaglutide | Jan 21, 2026 |
| Ziska Pharmaceuticals Limited | Bangladesh | 1 | 0 | Tirzepatide | May 6, 2024 |
| Zuellig Pharma Corp | Philippines | 1 | 0 | Tirzepatide | Jun 17, 2026 |
Declared manufacturers without a page
These lines count in every total and country table above. A refusal line names the declared manufacturer as entered and does not show who shipped the product.
| Group | Refused lines | Why no page |
|---|---|---|
| Brand-name maker entered as declared manufacturer (Novo Nordisk, Eli Lilly, Bristol-Myers Squibb, Mitsubishi Tanabe, Takeda, AbbVie, AstraZeneca, Elanco, Embecta, GlaxoSmithKline) | 508 | The refusal line names the brand owner as the importer entered it; it does not show who shipped the product, so these names get no page. |
| Name truncated or mostly digits in FDA’s file | 12 | Names that stop at exactly 32 characters, end in a cut-off word or are mostly digits read as cut off in FDA’s file and cannot be tied to one firm, so they get no page. |
| Business name containing a personal name | 1 | Counted, not named. |
| Private individual or a name that does not read as a business | 80 | Counted, not named. |
API and powder code lines, most recent first
| FDA refusal charges | Shipment ID | |||||
|---|---|---|---|---|---|---|
| Oct 7, 2026 | SHANGHAI SHUNYI TRADE CO LTD | China | 61PIR74 TIRZEPATIDE (ANTI-DIABETIC) | NonSterile Powder | LACKS FIRM: The article is in package form and appears to not bear a label containing the name and place of business of the manufacturer, packer, or distributor. DRUG NAME: The article appears to be a drug and fails to bear the proprietary or established name and/or name and quantity of each active ingredient. | XXX-0763321-9/1/1 |
| Oct 7, 2026 | XU LIHUA JINGFANG Trading Co. LTD | China | 61PIR74 TIRZEPATIDE (ANTI-DIABETIC) | NonSterile Powder | LACKS FIRM: The article is in package form and appears to not bear a label containing the name and place of business of the manufacturer, packer, or distributor. INCONSPICU: Information required by the Act to be on the label or labeling does not appear to be conspicuous enough as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use. WARNINGS: It appears to lack adequate warning against use in a pathological condition or by children where it may be dangerous to health or against an unsafe dose, method, administering duration, application, in manner/form, to protect users. DRUG NAME: The article appears to be a drug and fails to bear the proprietary or established name and/or name and quantity of each active ingredient. | XXX-0763336-3/1/2 |
| Oct 7, 2026 | XU LIHUA JINGFANG Trading Co. LTD | China | 61PIR72 SEMAGLUTIDE (ANTI-DIABETIC) | NonSterile Powder | LACKS FIRM: The article is in package form and appears to not bear a label containing the name and place of business of the manufacturer, packer, or distributor. INCONSPICU: Information required by the Act to be on the label or labeling does not appear to be conspicuous enough as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use. WARNINGS: It appears to lack adequate warning against use in a pathological condition or by children where it may be dangerous to health or against an unsafe dose, method, administering duration, application, in manner/form, to protect users. DRUG NAME: The article appears to be a drug and fails to bear the proprietary or established name and/or name and quantity of each active ingredient. | XXX-0763336-3/1/4 |
| Sep 28, 2026 | Name not shown | China | 61PCR74 TIRZEPATIDE (ANTI-DIABETIC) | NonSterile Powder | DIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use. | XXX-0763136-5/1/1 |
| Sep 14, 2026 | BIOAMINO LABS | Germany | 61PCZ74 TIRZEPATIDE (ANTI-DIABETIC) | Sterile Powder | UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA). NOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k). FRNMFGREG: The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on information available to FDA, it appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under Section 510 of the Act. | XXX-0761571-4/1/1 |
| May 19, 2026 | NANJING HANXIN INTERNATIONAL | China | 61PCT72 SEMAGLUTIDE (ANTI-DIABETIC) | Active Pharm Ingred/Chems for Rx Compounding | DIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use. FALSEDRUG: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug which is misbranded within the meaning of section 502(a)(1) in that its labeling is false or misleading. | 1FX-1577805-2/10003/1 |
| May 14, 2026 | Hybio Pharmaceutical (Wuhan) Co., Ltd. | China | 61PCT72 SEMAGLUTIDE (ANTI-DIABETIC) | Active Pharm Ingred/Chems for Rx Compounding | NOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k). DIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use. FRNMFGREG: The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on information available to FDA, it appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under Section 510 of the Act. | 8NP-0144593-5/10002/1 |
| Feb 25, 2026 | Gene Proteins | Switzerland | 61PDZ74 TIRZEPATIDE (ANTI-DIABETIC) | Sterile Powder | UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA). | XXX-0735941-2/1/23 |
| Feb 9, 2026 | Hybio Pharmaceutical Co., Ltd. | China | 61PDR74 TIRZEPATIDE (ANTI-DIABETIC) | NonSterile Powder | FRNMFGREG: The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on information available to FDA, it appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under Section 510 of the Act. | 799-2538313-8/10003/1 |
| Feb 3, 2026 | HONG KONG KAIYS TRADING LIMITED | Hong Kong | 61PCZ74 TIRZEPATIDE (ANTI-DIABETIC) | Sterile Powder | UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA). NOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k). NO ENGLISH: Required label or labeling appears to not be in English in violation of 21 C.F.R. 801.15(c)(1) FRNMFGREG: The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on information available to FDA, it appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under Section 510 of the Act. | XXX-0732348-4/1/1 |
| Aug 6, 2025 | Harbin Jixianglong Biotech Co., Ltd. | China | 61PCT72 SEMAGLUTIDE (ANTI-DIABETIC) | Active Pharm Ingred/Chems for Rx Compounding | DIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use. | H77-0229191-2/13/1 |
| May 28, 2025 | Fujian Genohope Biotech Ltd | China | 61PCT74 TIRZEPATIDE (ANTI-DIABETIC) | Active Pharm Ingred/Chems for Rx Compounding | DIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use. | BYA-2502829-1/12/1A |
| May 28, 2025 | Fujian Genohope Biotech Ltd | China | 61PCT74 TIRZEPATIDE (ANTI-DIABETIC) | Active Pharm Ingred/Chems for Rx Compounding | DIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use. | BYA-2502829-1/12/1B |
| May 19, 2025 | DYNAMIC GROUP | Canada | 61PCR74 TIRZEPATIDE (ANTI-DIABETIC) | NonSterile Powder | UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA). NOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k). DIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use. | SCS-0245881-3/13/1C |
| May 14, 2025 | XIAMEN YUANJINCHEN TRADING CO,.LTD | China | 61PCT74 TIRZEPATIDE (ANTI-DIABETIC) | Active Pharm Ingred/Chems for Rx Compounding | UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA). NOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k). DIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use. FRNMFGREG: The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on information available to FDA, it appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under Section 510 of the Act. | N30-0040640-4/13/1 |
| May 1, 2025 | Hangzhou ThinHeal Pharma-Tech Co., Ltd. | China | 61PCT72 SEMAGLUTIDE (ANTI-DIABETIC) | Active Pharm Ingred/Chems for Rx Compounding | NOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k). FRNMFGREG: The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on information available to FDA, it appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under Section 510 of the Act. | BYA-2501606-4/12/1 |
| May 1, 2025 | Hangzhou ThinHeal Pharma-Tech Co., Ltd. | China | 61PCT74 TIRZEPATIDE (ANTI-DIABETIC) | Active Pharm Ingred/Chems for Rx Compounding | NOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k). FRNMFGREG: The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on information available to FDA, it appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under Section 510 of the Act. | BYA-2501606-4/12/2 |
| Feb 28, 2025 | Fujian Genohope Biotech Ltd | China | 61PCT74 TIRZEPATIDE (ANTI-DIABETIC) | Active Pharm Ingred/Chems for Rx Compounding | FRNMFGREG: The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on information available to FDA, it appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under Section 510 of the Act. | BYA-2500742-8/11/1 |
| Feb 28, 2025 | Fujian Genohope Biotech Ltd | China | 61PCT74 TIRZEPATIDE (ANTI-DIABETIC) | Active Pharm Ingred/Chems for Rx Compounding | FRNMFGREG: The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on information available to FDA, it appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under Section 510 of the Act. | BYA-2500742-8/11/2 |
| Feb 28, 2025 | Fujian Genohope Biotech Ltd | China | 61PCT74 TIRZEPATIDE (ANTI-DIABETIC) | Active Pharm Ingred/Chems for Rx Compounding | FRNMFGREG: The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on information available to FDA, it appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under Section 510 of the Act. | BYA-2500742-8/11/3 |
| Oct 28, 2024 | Fujian Genohope Biotech Ltd | China | 61PCS72 SEMAGLUTIDE (ANTI-DIABETIC) | Active Pharm Ingred/Chems for Further Manuf | NOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k). FRNMFGREG: The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on information available to FDA, it appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under Section 510 of the Act. | AEK-5719160-1/11/1 |
| Oct 28, 2024 | Fujian Genohope Biotech Ltd | China | 61PCS74 TIRZEPATIDE (ANTI-DIABETIC) | Active Pharm Ingred/Chems for Further Manuf | NOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k). | AEK-5719160-1/21/1 |
| Aug 5, 2024 | Hubei JXBio Pharmaceutical Co., Ltd. | China | 61PCZ74 TIRZEPATIDE (ANTI-DIABETIC) | Sterile Powder | UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA). | XXX-0614347-6/1/1 |
| Apr 30, 2024 | JBL INTERNATIONAL HK LIMITED | Hong Kong | 61PCT74 TIRZEPATIDE (ANTI-DIABETIC) | Active Pharm Ingred/Chems for Rx Compounding | NOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k). FRNMFGREG: The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on information available to FDA, it appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under Section 510 of the Act. | 799-0740432-2/11/1 |
| Jan 25, 2024 | Qingdao Biopeptek Co., Ltd. | China | 61PCR72 SEMAGLUTIDE (ANTI-DIABETIC) | NonSterile Powder | LACKS FIRM: The article is in package form and appears to not bear a label containing the name and place of business of the manufacturer, packer, or distributor. DIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use. | AEK-3647198-3/11/1 |
| Dec 6, 2023 | Qingdao Biopeptek Co., Ltd. | China | 61PCT72 SEMAGLUTIDE (ANTI-DIABETIC) | Active Pharm Ingred/Chems for Rx Compounding | LACKS FIRM: The article is in package form and appears to not bear a label containing the name and place of business of the manufacturer, packer, or distributor. DIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use. FALSEDRUG: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug which is misbranded within the meaning of section 502(a)(1) in that its labeling is false or misleading. | AEK-3571990-3/11/1 |
| Dec 6, 2023 | Qingdao Biopeptek Co., Ltd. | China | 61PCT74 TIRZEPATIDE (ANTI-DIABETIC) | Active Pharm Ingred/Chems for Rx Compounding | DIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use. FALSEDRUG: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug which is misbranded within the meaning of section 502(a)(1) in that its labeling is false or misleading. | AEK-3572197-4/11/1 |
| Nov 27, 2023 | SHENZHEN JYMED TECHNOLOGY CO., LTD. | China | 61PCZ74 TIRZEPATIDE (ANTI-DIABETIC) | Sterile Powder | UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA). | 799-7891447-1/11/1 |
| Oct 11, 2023 | Zhejiang Peptites Biotech Co.,Ltd. | China | 61PDT72 SEMAGLUTIDE (ANTI-DIABETIC) | Active Pharm Ingred/Chems for Rx Compounding | DIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use. | 906-0395480-4/11/1 |
| Sep 27, 2023 | Zhejiang Peptites Biotech Co.,Ltd. | China | 61PDT72 SEMAGLUTIDE (ANTI-DIABETIC) | Active Pharm Ingred/Chems for Rx Compounding | DIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use. | 8V8-0000195-1/11/2 |
| Sep 7, 2023 | Zhejiang Peptites Biotech Co.,Ltd. | China | 61PCT72 SEMAGLUTIDE (ANTI-DIABETIC) | Active Pharm Ingred/Chems for Rx Compounding | DIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use. | 8GX-8000731-3/11/1 |
| Aug 30, 2023 | Zhejiang Peptites Biotech Co.,Ltd. | China | 61PCZ74 TIRZEPATIDE (ANTI-DIABETIC) | Sterile Powder | UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA). NOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k). | 390-9824420-3/11/1B |
Other FDA import alerts searched
Each alert page below was read on Nov 15, 2026 and its text searched for semaglutide, tirzepatide, liraglutide, retatrutide and GLP-1. Alerts not in this table were not searched.
| Times the page names semaglutide, tirzepatide, liraglutide, retatrutide or GLP-1 | |||
|---|---|---|---|
| 66-80: Detention Without Physical Examination of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Bulk Drug Substances | Oct 9, 2026 | GLP-1 32, semaglutide 15, tirzepatide 14, liraglutide 14 | 17 |
| 66-41: Detention Without Physical Examination of Unapproved New Drugs Promoted In The U.S. | Nov 12, 2026 | GLP-1 5 | 1 |
| 66-40: Detention Without Physical Examination of Drugs From Firms Which Have Not Met Drug GMPs | Nov 12, 2026 | None | 0 |
| 66-66: APIs That Appear To Be Misbranded Under 502(f)(1) Because They Do Not Meet The Requirements For The Labeling Exemptions In 21 CFR 201.122 | Oct 22, 2024 | None | 0 |
| 66-72: Detention Without Physical Examination Of Misbranded Drugs And Marketed New Drugs Without Approved Applications | Oct 15, 2026 | None | 0 |
| 66-78: Detention Without Physical Examination of Drugs, Based Upon Analytic Test Results | Jul 9, 2026 | None | 0 |
| 66-79: Detention Without Physical Examination of Drugs From Foreign Establishments Refusing FDA Inspection | Sep 23, 2026 | None | 0 |
| 66-57: Detention Without Physical Examination of Foreign Manufactured Unapproved Prescription Drugs Distributed to Individuals in the U.S. | Mar 23, 2026 | None | 0 |
| 66-76: Detention Without Physical Examination of Drugs or Active Pharmaceutical Ingredients From Facilities That Have Not Submitted Self-Identifying Information or Paid Facility or Program Fees Required Under GDUFA | Mar 26, 2025 | None | 0 |
| 54-16: DETENTION WITHOUT PHYSICAL EXAMINATION OF PRODUCTS THAT ARE MARKETED AS FOODS, INCLUDING PRODUCTS MARKETED AS DIETARY SUPPLEMENTS, THAT CONTAIN AN ACTIVE PHARMACEUTICAL INGREDIENT | Oct 15, 2026 | None | 0 |
| 55-05: Detention Without Physical Examination Of Finished Dosage Form Drug Products, Active Pharmaceutical Ingredients, and Inactive Ingredients for Potentially Hazardous Microbiological Contamination | May 5, 2026 | None | 0 |
| 99-34: DETENTION WITHOUT PHYSICAL EXAMINATION OF DRUGS OR MEDICAL DEVICES FROM FIRMS WITHOUT A VALID DRUG OR MEDICAL DEVICE REGISTRATION AND/OR LISTING | Nov 2, 2026 | None | 0 |
Listed firms whose entries name a GLP-1 term
| Alert and list | Firm | Country | Products as FDA lists them |
|---|---|---|---|
| 66-41, Red List added Jun 23, 2026 | Hebei Houde Hanfang Medical Devices Co., Ltd. Jinhe Int'L Business Bldg. A Room 1603, Huaan West Street, Shijiazhuang, Hebei CHINA | CHINA | 66V--99 Miscellaneous Patent Medicines, Etc.: GLP-1 Transdermal Patches 66V--99 Miscellaneous Patent Medicines, Etc.: Adhesive Patch 66Y--99 Exhibits - Other Drug Related Items N.E.C.: GLP-1 Transdermal Patches 66Y--99 Exhibits - Other Drug Related Items N.E.C.: Adhesive Patch 79K--GX Tape And Bandage, Adhesive: GLP-1 Transdermal Patches 79K--GX Tape And Bandage, Adhesive: Adhesive Patch 80K--ME Bedding, Disposable, Medical: GLP-1 Transdermal Patches 80K--ME Bedding, Disposable, Medical: Adhesive Patch 80Q--IX System, transdermal Ddlivery, CDER or CBER led: GLP-1 Transdermal Patches 80Q--IX System, transdermal Ddlivery, CDER or CBER led: Adhesive Patch |
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
- FDA Import Alert 66-80
- FDA Import Refusal Report bulk files
- FDA Data Dashboard: import refusals
- FDA import alerts by number
Records last pulled Nov 15, 2026. Every entry links to the original public record.